Clinical practice consensus for the diagnosis and management of melanoma in Taiwan
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Date Issued
2024
Author(s)
Wu, Chiao-En
Wu, Cheng-Lin
Yang, Muh-Hwa
Yen, Chueh-Chuan
Su, Wu-Chou
Yen, Chia-Jui
Chang, Yi-Fang
Wu, Ming-Fang
Yang, Youngsen
Lin, Chen-Yuan
Yang, Wen-Chi
Wang, Hui-Ching
Li, Cheng-Yuan
Ho, Yin-Yu
Chang, Yao-Yu
Wu, Chieh-Shan
Hsu, Hsiu-Cheng
Chen, Kuang-Hua
Huang, Yenlin
Chen, Chih-Jung
Chuang, Pei-Ju
Lai, Yung-Chi
Huang, Yu-Yi
Tseng, Neng-Chuan
Huang, Yi-Ting
Wen-Cheng Chang, John
Abstract
Melanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of the clinical guidelines in Western countries, Taiwanese experts developed a local clinical practice consensus guideline. This consensus includes diagnosis, staging, and surgical and systemic treatment, based only on clinical evidence, local epidemiology, and available resources evaluated by experts in Taiwan. This consensus emphasizes the importance of surgical management, particularly for sentinel lymph node biopsies. In addition, molecular testing for BRAF is mandatory for patients before systemic treatment. Furthermore, immunotherapy and targeted therapy are prioritized for systemic treatment. This consensus aimed to assist clinicians in Taiwan in diagnosing and treating patients according to available evidence.
Subjects
Acral melanoma
Immunotherapy
Melanoma
Mucosal melanoma
Targeted therapy
SDGs
Type
journal article